» Articles » PMID: 37834217

Metabolomic Signatures of Alzheimer's Disease Indicate Brain Region-Specific Neurodegenerative Progression

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Oct 14
PMID 37834217
Authors
Affiliations
Soon will be listed here.
Abstract

Pathological mechanisms contributing to Alzheimer's disease (AD) are still elusive. Here, we identified the metabolic signatures of AD in human post-mortem brains. Using H NMR spectroscopy and an untargeted metabolomics approach, we identified (1) metabolomic profiles of AD and age-matched healthy subjects in post-mortem brain tissue, and (2) region-common and region-unique metabolome alterations and biochemical pathways across eight brain regions revealed that BA9 was the most affected. Phenylalanine and phosphorylcholine were mainly downregulated, suggesting altered neurotransmitter synthesis. N-acetylaspartate and GABA were upregulated in most regions, suggesting higher inhibitory activity in neural circuits. Other region-common metabolic pathways indicated impaired mitochondrial function and energy metabolism, while region-unique pathways indicated oxidative stress and altered immune responses. Importantly, AD caused metabolic changes in brain regions with less well-documented pathological alterations that suggest degenerative progression. The findings provide a new understanding of the biochemical mechanisms of AD and guide biomarker discovery for personalized risk prediction and diagnosis.

Citing Articles

Metabolic Profiling of Brain Tissue and Brain-Derived Extracellular Vesicles in Alzheimer's Disease.

Hernandez P, Rackles E, Alboniga O, Martinez-Lage P, Camacho E, Onaindia A J Extracell Vesicles. 2025; 14(2):e70043.

PMID: 39901643 PMC: 11791017. DOI: 10.1002/jev2.70043.


Oxidized low-density lipoprotein changes the inflammatory status and metabolomics profiles in human and mouse macrophages and microglia.

Sun Y, Liang J, Xu J, Zhou K, Fu C, Chen S Heliyon. 2024; 10(7):e28806.

PMID: 38617955 PMC: 11015420. DOI: 10.1016/j.heliyon.2024.e28806.


Unraveling Metabolic Changes following Stroke: Insights from a Urinary Metabolomics Analysis.

Petersson J, Bykowski E, Ekstrand C, Dukelow S, Ho C, Debert C Metabolites. 2024; 14(3).

PMID: 38535305 PMC: 10972298. DOI: 10.3390/metabo14030145.


Blood-Derived Metabolic Signatures as Biomarkers of Injury Severity in Traumatic Brain Injury: A Pilot Study.

Bykowski E, Petersson J, Dukelow S, Ho C, Debert C, Montina T Metabolites. 2024; 14(2).

PMID: 38392997 PMC: 10890255. DOI: 10.3390/metabo14020105.

References
1.
Nelson P, Alafuzoff I, Bigio E, Bouras C, Braak H, Cairns N . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012; 71(5):362-81. PMC: 3560290. DOI: 10.1097/NEN.0b013e31825018f7. View

2.
Mirra S, HEYMAN A, McKeel D, SUMI S, Crain B, Brownlee L . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41(4):479-86. DOI: 10.1212/wnl.41.4.479. View

3.
Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

4.
Polis B, Samson A . Role of the metabolism of branched-chain amino acids in the development of Alzheimer's disease and other metabolic disorders. Neural Regen Res. 2020; 15(8):1460-1470. PMC: 7059578. DOI: 10.4103/1673-5374.274328. View

5.
Wissmann P, Geisler S, Leblhuber F, Fuchs D . Immune activation in patients with Alzheimer's disease is associated with high serum phenylalanine concentrations. J Neurol Sci. 2013; 329(1-2):29-33. DOI: 10.1016/j.jns.2013.03.007. View